Sparian Biosciences is a clinical stage bio-pharmaceutical company based in New York, NY, dedicated to the discovery and development of innovative therapies targeting the central nervous system (CNS).
Recently, Sparian Biosciences was awarded a prestigious $19 million five-year NIH NIDA grant to support the development of SBS-518, a potential treatment for Stimulant Use Disorder, through Phase 1 clinical trials.
Generated from the website